Abstract
Daiichi Sankyo's core strategy is to become a Japanese "Global Pharma
Innovator". This report provides a full review of the company's activities
together with sales forecasts for key products to 2010.
For the nine months ended 31st December 2005, Daiichi Sankyo's net sales were
¥704,039 million. Operating income was ¥134,294 million and net income was
¥80,992 million. Research and development expenditure was ¥113,371 million and
pharmaceutical sales were ¥606,349 million.
Key products
Daiichi Sankyo intends to maximise the value of its existing leading products,
beyond what could have been achieved by the companies separately. For example:
- Daiichi Sankyo is undertaking life-cycle management of the
antihypertensive, Olmetec/Benicar, which is one of the companies main
growth drivers. Since its introduction in a number of markets, sales and
market share are increasing.
- The future growth of the anti-infective Cravit is expected to be
strong due to life-cycle management efforts.
- In fiscal 2005, sales of the antihypertensive, Calblock, increased
by 400%, to reach ¥3,000 million and are forecast to exceed ¥10 billion in
Japan.
Overseas pharmaceutical sales were negatively affected by the expiration of
the patent in certain European countries for pravastatin and increasing
competition faced by that product in the US, which weakened sales of bulk
pravastatin. However, sales of olmesartan and levofloxacin were strong.
Major Products Forecast to 2010
- Cravit (Antibacterial)
- Omnipaque (Contrast agent)
- Panaldine (Cardiovascular)
- Artist (Cardiovascular)
- Sunrythm (Cardiovascular)
- Zyrtec (Anti-inflammatory)
- Mevalotin (Cardiovascular)
- Loxonin (Anti-infective)
- Remacin (Haematological)
- Acecol (Cardiovascular)
- Banan (Antibacterial)
- Espo (Haematological)
- Carbenin (Antibacterial)
- Gran (Anticancer)
- Alesion (Anti-allergenic)
- Olmetec (Cardiovascular)
| 
View Cart
